LifeMD Inc. (LFMD)
NASDAQ (NMS) NASDAQ (NMS) Primary 
LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript
LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript
LifeMD Q2 Earnings Call Highlights
LifeMD NASDAQ: LFMD reported second-quarter revenue of $47.3 million, within its prior guidance range, while posting an adjusted EBITDA loss of approximately $3.5 million as elevated customer acquisition costs and a lower introductory price for branded GLP-1 care pressured profitability.
LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.06 per share a year ago.
LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.01 per share a year ago.
LifeMD: Wegovy Pill, Net Cash, And Low Multiple Sets Up Longs For Possible Alpha
LifeMD is rated Buy, trading at a low 0.796x TTM sales, with upside if multiples revert. LFMD's strategic divestment of WorkSimpli refocused the business as a pure-play telehealth and pharmacy provider. The recent launch of the Wegovy pill will expand growth from its GLP-1 vertical.
LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.
LifeMD: Still My Favorite Bargain On The Market
LifeMD remains a deeply undervalued telehealth stock, now trading with significant pessimism priced in after a 55% decline. LFMD's business model faces risks from slowing growth, legal issues, competition, and a disappointing WorkSimpli sale, but the fundamental story remains intact. Preferred shares yield just under 10% and offer lower risk, but I favor the common stock for its substantial upside potential at current prices.
LifeMD: Pure Telehealth Play With In-House Pharmacy Integration
LifeMD is rated a buy with an FY 2026 target price of ~$6, implying over 85% upside from current levels. LFMD's shift to a pure-play telehealth model, divesting WorkSimpli, and integrating in-house pharmacy capabilities are expected to drive growth and margin expansion. Regulatory approval for 503-A compounding pharmacy and the Novo Nordisk Wegovy partnership are highlighted as key catalysts for profitability and differentiation.
LifeMD, Inc. (LFMD) Q3 2025 Earnings Call Transcript
LifeMD, Inc. ( LFMD ) Q3 2025 Earnings Call November 17, 2025 4:30 PM EST Company Participants Justin Schreiber - Chairman & CEO Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Sarah James - Cantor Fitzgerald & Co., Research Division Eduardo Martinez-Montes - H.C.
LifeMD, Inc. (LFMD) Reports Q3 Loss, Misses Revenue Estimates
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.14 per share a year ago.
LifeMD: Set To Ride A Telehealth Tailwind
LifeMD shares nearly halved in price following a missed earnings report, with subscriber retention being a key issue. LifeMD stock trades at a significant discount to HIMS despite similar subscription models and industry tailwinds, so I believe a rerating is on the table. The service is inherently sticky, and subscribers are unlikely to switch. The industry is still young, and telehealth is gaining adoption.
